Altimmune Reports Q2 2025 Financial Results with Reduced Net Loss and Increased Cash Reserves

Altimmune, Inc. reported its financial results for the second quarter of 2025, revealing a net loss of $22.1 million, a decrease from a net loss of $24.6 million in the same period last year. The company’s revenues remained unchanged at $5,000 for both the second quarter of 2025 and 2024, reflecting its ongoing status as a clinical-stage biopharmaceutical firm without product sales. Total operating expenses for the quarter decreased by 14% to $22.9 million, down from $26.8 million in the prior year, primarily due to reduced research and development costs associated with its lead program, pemvidutide.

For the first half of 2025, Altimmune reported a net loss of $41.7 million, compared to a loss of $49.0 million for the same period in 2024. Total operating expenses for the six months ended June 30, 2025, were $44.7 million, a 16% decrease from $53.5 million in the previous year. The reduction in expenses was attributed to a significant decline in research and development costs, which fell by 22% to $33.1 million, largely due to decreased spending on the MASH program as the company progressed through its clinical trials.

In terms of liquidity, Altimmune's cash, cash equivalents, and restricted cash increased significantly to $183.1 million as of June 30, 2025, up from $36.9 million at the end of 2024. This increase was bolstered by $72.6 million in net proceeds from at-the-market offerings and a $15 million term loan secured in May 2025. The company has indicated that it believes its current cash reserves are sufficient to fund operations for at least the next twelve months, although it may seek additional financing to support ongoing clinical trials and operational needs.

Operationally, Altimmune is advancing its clinical programs, particularly with pemvidutide, which is being evaluated for multiple indications including metabolic dysfunction-associated steatohepatitis (MASH), Alcohol Use Disorder (AUD), and Alcohol-Associated Liver Disease (ALD). The company recently reported positive topline results from the Phase 2b IMPACT trial for MASH, demonstrating significant efficacy in achieving MASH resolution and weight loss among treated subjects. The company is also actively enrolling patients in trials for AUD and ALD, indicating a strategic focus on expanding its product pipeline.

Looking ahead, Altimmune remains committed to its clinical development strategy while navigating the challenges of the biopharmaceutical landscape. The company is focused on leveraging its cash position to advance its clinical trials and potentially explore partnerships or additional financing options to support its growth objectives.